RLS and SOFIE Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients
LAKE ZURICH, Il. and DULLES, Va. — June 21, 2023, RLS (USA), […]
Current State of FAP Ligands for Diagnostic Use in Oncology
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
June 14, 2023 Download the Presentation […]
Focus on FAPI Newsletter – Q2 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI community,
This quarter, the FAPI team celebrated […]
SOFIE partners with BAMF Health, diversifying sites for Phase II [68Ga]FAPI-46 study
SOFIE has added BAMF Health, a novel cancer treatment center in Grand Rapids, Michigan, as […]
First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial
Dulles, VA –May 12, 2023 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
FAPI Theragnostics
Presented by: Prof. Dr. Frederik L. Giesel, MD, MBA; Chair of Nuclear Medicine, Department of […]
Fibroblast Activation Protein (FAP) Inhibitors as Biomarkers in Oncology, Fibrotic Disease, and Cardiovascular Disease
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
Informa Connect: Radiopharmaceuticals and Imaging Digital Conference
March […]
Focus on FAPI Newsletter – Q4 2023
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI community,
We would like to wish you […]
